GSEP
TLIS

Golden State Equity Partners’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Golden State Equity Partners’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$31K Hold
1,476
– – 0.02% 190
2021
Q4 		$89K Buy
+1,476
New +$110K 0.05% 167

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Golden State Equity Partners's TLIS Position: Q1 2022 in Review

Golden State Equity Partners held its Talis Biomedical Corporation Common Stock (TLIS) position steady in Q1 2022 at 1,476 shares worth $31K. The position accounts for 0.02% of the portfolio, ranked #190.

Golden State Equity Partners first reported a position in TLIS in Q4 2021 and has held it in 2 quarters since. The position peaked at $89K in Q4 2021. 44 funds tracked by Wall St. Rank hold TLIS as of Q1 2022.

  • Golden State Equity Partners held 1,476 shares of Talis Biomedical Corporation Common Stock worth $31K as of Q1 2022.
  • Golden State Equity Partners left its Talis Biomedical Corporation Common Stock share count unchanged in Q1 2022.
  • Talis Biomedical Corporation Common Stock made up 0.02% of Golden State Equity Partners's portfolio in Q1 2022, its #190 holding.
  • Golden State Equity Partners first reported a position in Talis Biomedical Corporation Common Stock in Q4 2021 and has held it in 2 quarters since.
  • Golden State Equity Partners's Talis Biomedical Corporation Common Stock position peaked at $89K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q1 2022.

Based on Golden State Equity Partners's 13F filing for Q1 2022, filed 16 May 2022.